Nasopharyngeal carcinoma (NPC) is a head and neck cancer with unbalanced geographical distribution; it is particularly prevalent in Southern China, East and Southeast Asia, and North Africa.
1 Worldwide, approximately 129 000 new cases of NPC and 73 000 deaths attributed to this disease are reported annually.
2 The incidence of synchronous metastatic disease is about 5% in newly diagnosed patients. In addition, about 20% of patients with nonmetastatic NPC develop distant failure even after definitive treatments, which remains a main cause of death in these patients.
3,4 Taken together, approximately one-fourth of patients with NPC eventually experience metastatic diseases that require systemic therapy.